Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models

Prostate

Volumn 74, Issue 8, 2014, Pages 852-868

  Gravina, Giovanni Luca ^a,b   Marampon, Francesco ^a   Sherris, David ^c   Vittorini, Francesca ^d   Cesare, Ernesto Di ^a   Tombolini, Vincenzo ^a,b   Lenzi, Andrea ^b   Jannini, Emmanuele A ^a   Festuccia, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Paloma Pharmaceuticals   (United States)

^d SAN SALVATORE HOSPITAL   (Italy)

Author keywords

CRM1; GSK 3 ; P529; prostate cancer; radiotherapy; survivin; TORC1 TORC2

Indexed keywords

CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; KU ANTIGEN; MYC PROTEIN; PALOMID 529; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAD51 PROTEIN; RADIOSENSITIZING AGENT; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CLONOGENESIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIZATION; SENESCENCE; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

CRM1; GSK-3Β; P529; PROSTATE CANCER; RADIOTHERAPY; SURVIVIN; TORC1/TORC2;

ANIMALS; BENZOPYRANS; CELL LINE, TUMOR; DNA REPAIR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KARYOPHERINS; MALE; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TOR SERINE-THREONINE KINASES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899587156     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22804     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M,. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 2005; 12 (4): 983-998.
3. Gravina GL, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V, Festuccia C,. Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol 2009; 35 (5): 1133-1139.
4. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J,. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006; 208: 699-707.
5. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL,. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275: 24500-24505.
6. Uzgare AR, Isaacs JT,. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004; 64: 6190-6199.
7. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, Bologna M,. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 2007; 14: 601-611.
8. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM,. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-3867.
9. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M,. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008; 68: 965-974.
10. Ahmed KM, Fan M, Nantajit D, Cao N, Li JJ,. Cyclin D1 in low-dose radiation-induced adaptive resistance. Oncogene 2008; 27: 6738-6748.
11. Alt JR, Gladden AB, Diehl JA,. p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 2002; 277: 8517-8523.
12. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS,. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem. 2003; 278: 48872-48879.
13. Yuan J, Zhang J, Wong BW, Si X, Wong J, Yang D, Luo H,. Inhibition of glycogen synthase kinase 3beta suppresses coxsackie virus-induced cytopathic effect and apoptosis via stabilization of beta-catenin. Cell Death Differ 2005; 12: 1097-1106.
14. Schütz SV, Cronauer MV, Rinnab L,. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 2010; 109: 1192-1200.
15. Kaga S, Zhan L, Altaf E, Maulik N,. Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 2006; 40: 138-1347.
16. Li J, Xing M, Zhu M, Wang X, Wang M, Zhou S, Li N, Wu R, Zhou M,. Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett 2008; 272: 91-101.
17. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M, Rodemann HP,. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008; 7: 1772-1781.
18. Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G,. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res 1999; 152: 404-411.
19. Miura Y, Oxidative stress,. radiation-adaptive responses, and aging. J. Radiat. Res 2004; 45: 357-372.
20. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE,. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008; 68: 9551-9557.
21. Gravina GL, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V, Festuccia C,. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr Relat Cancer 2011; 18: 385-400.
22. Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, Serrano D, Redrado M, Sherris D, Calvo A,. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009; 100: 932-940.
23. McKenna WG, Muschel RJ,. Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer 2003; 38: 330-338.
24. Cheng JC, Chou CH, Kuo ML, Hsieh CY,. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006; 25: 7009-7018.
25. Craft N, Shostak Y, Carey M, Sawyers CL,. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-291.
26. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET,. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47: 212-220.
27. Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, Zani BM,. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 2011; 10: 159-168.
28. Gravina GL, Festuccia C, Angelucci A, Poletti A, Capuano D, Vicentini C, Motta M, Bologna M,. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol 2004; 25 (1): 97-104.
29. Narayan RS, Fedrigo CA, Stalpers LJ, Baumert BG, Sminia P,. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr Pharm Des 2013; 19 (5): 951-957.
30. Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJ,. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks. Cancer Res 2013; 73 (11): 3393-3401.
31. D'Andrea FP, Horsman MR, Kassem M, Overgaard J, Safwat A,. Tumourigenicity and radiation resistance of mesenchymal stem cells. Acta Oncol 2012; 51 (5): 669-679.
32. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, Vellanki SH, Hehlgans S, Rödel F, Debatin KM, Ludolph AC, Fulda S,. NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis. Mol Cancer Ther 2011; 10 (10): 1867-1875.
33. Josset E, Burckel H, Noël G, Bischoff P,. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res 2013; 33 (5): 1845-1851.
34. Gwak HS, Kim TH, Jo GH, Kim YJ, Kwak HJ, Kim JH, Yin J, Yoo H, Lee SH, Park JB,. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS ONE 2012; 7 (10): e47449.
35. Comincini S,. Autophagy and ionizing radiation in tumors: The "survive or not survive" dilemma. J Cell Physiol 2013; 228 (1): 1-8.
36. Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM, Condorelli G,. c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity. Cell Death Differ 2010; 17: (12). 1908-1916.
37. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV,. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol 2010; 24 (6): 1136-1150.
38. Xu C, Kim NG, Gumbiner BM,. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009; 8 (24): 4032-4039.
39. Yang ES, Nowsheen S, Wang T, Thotala DK, Xia F,. Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro Oncol 2011; 13 (5): 459-470.
40. Rodríguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G,. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res 2002; 275 (1): 44-53.
41. Knauer SK, Krämer OH, Knösel T, Engels K, Rödel F, Kovács AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rödel C, Mann W, Petersen I, Heinzel T, Stauber RH,. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007; 21 (1): 207-216.
42. Grdina DJ, Murley JS, Miller RC, Mauceri HJ, Sutton HG, Li JJ, Woloschak GE, Weichselbaum RR,. A survivin-associated adaptive response in radiation therapy. Cancer Res 2013; 73 (14): 4418-4428.
43. Chan KS, Wong CH, Huang YF, Li HY,. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010; 1: e57.
44. Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C,. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90 and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer 2013; 20 (3): 321-337.
45. Farnebo L, Tiefenböck K, Ansell A, Thunell LK, Garvin S, Roberg K,. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer 2013; 133 (8): 1994-2003.
46. Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Okumura Y, Yamaguchi L, Fujiki Y, Iwase H,. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: A comparative study at the mRNA and protein level. Breast Cancer. 2012 Sep 12. [Epub ahead of print]